Development of mRNA rabies vaccines
Open Access
- 28 July 2024
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20 (1) , 2382499
Abstract
Rabies, primarily transmitted to humans by dogs (accounting for 99% of cases). Once rabies occurs, its mortality rate is approximately 100%. Post-exposure prophylaxis (PEP) is critical for preventing the onset of rabies after exposure to rabid animals, and vaccination is a pivotal element of PEP. However, high costs and complex immunization protocols have led to poor adherence to rabies vaccinations. Consequently, there is an urgent need to develop new rabies vaccines that are safe, highly immunogenic, and cost-effective to improve compliance and effectively prevent rabies. In recent years, mRNA vaccines have made significant progress in the structural modification and optimization of delivery systems. Various mRNA vaccines are currently undergoing clinical trials, positioning them as viable alternatives to the traditional rabies vaccines. In this article, we discuss a novel mRNA rabies vaccine currently undergoing clinical and preclinical testing, and evaluate its potential to replace existing vaccines.Keywords
This publication has 93 references indexed in Scilit:
- Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene ProductJournal of Virology, 2002
- Economic Issues in Postexposure Rabies TreatmentJournal of Travel Medicine, 1999
- Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cellsVaccine, 1999
- Highly stable expression of a foreign gene from rabies virus vectors.Proceedings of the National Academy of Sciences, 1996
- Purification of a Secreted Form of Recombinant Rabies Virus Glycoprotein: Comparison of Two Affinity TagsProtein Expression and Purification, 1996
- Mechanisms of Rabies Virus NeutralizationVirology, 1993
- Antigenicity of rabies virus glycoproteinJournal of Virology, 1991
- Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectorsVirology, 1989
- Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on Vero cellsVaccine, 1989
- Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoproteinJournal of Virology, 1985